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Vitamin K2 supplementation in haemodialysis patients 
 
 
Abstract 
 
Cardiovascular disease is the leading cause of morbidity and mortality in 
patients with end-stage renal disease undergoing haemodialysis. In these 
patients there is a high incidence of severe arterial calcification, and this in 
turn has been linked to vitamin K2 deficiency. In this article we have therefore 
reviewed the potential role of vitamin K2 supplementation in reducing arterial 
calcification, and hence the risk of cardiovascular mortality, in haemodialysis 
patients. 
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calcification. 
 
 
Introduction 
Cardiovascular disease is the leading cause of morbidity and mortality in 
patients with end-stage renal disease undergoing haemodialysis (Quack & 
Westenfeld, 2016). In these patients there is a high incidence of severe arterial 
calcification, and this in turn has been linked to vitamin K2 deficiency (Blacher 
et al, 2001; Jean et al, 2009; Noordzij et al, 2011). In this article we have 
therefore reviewed the potential role of vitamin K2 supplementation in 
reducing arterial calcification, and hence the risk of cardiovascular mortality, in 
haemodialysis patients. 
 
Vitamin K basics 
The term vitamin K refers to a group of fat-soluble substances of related 
chemical structure. Vitamins K1 and K2 are of natural origin; other types of 
vitamin K (e.g. vitamin K3, menadione) are synthetic. In terms of evidence 
from controlled clinical trials, vitamin K of natural origin is considered to be 
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superior (in terms of efficacy and safety) to the synthetic forms. Concerns 
have been raised regarding possible toxicity of menadione, the synthetic form 
vitamin K3 (Chiou et al, 1997). Vitamin K1 (also known as phylloquinone) is 
mainly of plant origin, vitamin K2 (also known as menaquinone) is mainly of 
animal origin, being produced by bacteria in the intestinal tract (either in farm 
animals or man). In man, approx 50% of the body’s K2 requirement is 
obtained from the diet, and 50% synthesised within the human digestive tract 
(Schurgers et al., 2000). A form of vitamin K2 obtained from the Japanese 
fermented soybean food natto (a uniquely rich dietary source of K2) is called 
Menaquinone-7 (MK-7), the importance of which will be discussed in more 
detail in this paper.   An adequate intake of vitamin K1 can be achieved by 
regular consumption of green leafy vegetables such as spinach and kale. An 
adequate intake of vitamin K2 is more difficult to achieve; vitamin K2 can be 
obtained from eggs and dairy products, with estimated values of 70mcg per 
100g cheese, 30mcg per 100g egg yolk and 15mcg per 100g butter.  It is 
important that these foods are obtained from grass-fed cows or hens, since 
produce from intensively reared livestock contain substantially lower levels of 
vitamin K2. The values for the above foods compare with a vitamin K2 content 
of approximately 1100mcg per 100g of natto. 
 
Functions of vitamin K2 
Both vitamin K1 and K2 are converted within the body into the active form 
dihydrovitamin K, which in turn is a key co-factor of the enzyme gamma 
glutamyl carboxylase. Gamma glutamyl carboxylase activates (via 
carboxylation) calcium binding proteins involved in blood clotting, bone 
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structure and cardiovascular function. Of the two natural forms of vitamin K, 
vitamin K2 is considered to be superior to vitamin K1, in terms of 
bioavailability and effectiveness within the body (Schwalfenberg, 2017). For 
example, vitamin K2 (in MK-7 form) is more easily absorbed from the digestive 
tract, is retained longer within the body, has a wider tissue distribution, and 
has greater metabolic action, compared to vitamin K1 (Schurgers et al, 2007).  
 
Intestinal absorption of vitamin K2 occurs as for other lipid soluble substances. 
In the duodenum, vitamin K2 is subject to the process of  micellisation, 
through which lipid soluble substances are prepared for intestinal absorption. 
Bile from the gall bladder is secreted into the duodenum, and substances 
present in bile interact with vitamin K2 molecules to form characteristic 
micellular spherical structures up to 20nm in diameter.  Micelles are small 
enough to diffuse between intestinal villi, thereby transporting vitamin K2 to 
the surface of enterocytes prior to absorption. Enterocyte cells forming the 
lining of the small intestine villi absorb vitamin K2 via a process of passive  
diffusion (passive means the process does not require energy). This passive 
diffusion process is influenced by levels of unsaturated fatty acids, bile salts 
and luminal pH, factors relevant to patients who may have undergone bowel 
surgery. Once inside the enterocyte, vitamin K2 is incorporated into  
chylomicrons, lipoprotein based particles designed for the transport of lipid 
soluble substances in the circulation. Chylomicrons are released by exocytosis 
from the basal surface of enterocytes into the lymphatic system.   Vitamin K2 
containing chylomicrons eventually access the subclavian vein (via the 
proximal abdominal and thoracic lymph ducts), for systemic circulation.  
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following first pass repackaging in the liver via binding to LDL cholesterol for 
systemic transport within the bloodstream. On this basis, vitamin K2 
supplements are most efficiently absorbed in capsule form with a carrier oil 
matrix, which promotes micelle formation (Knapen et al, 2014). 
 
Patients with bone weakening often had calcified deposits within their blood 
vessels was recognised more than 100 years ago, although the role of vitamin 
K2 in this process was not understood at the time. Vitamin K2 activates the 
proteins matrix Gla protein (MGP) and osteocalcin, which transfer calcium from 
the lining of arteries into the bone matrix respectively (Villa et al, 2017). In 
addition to bone disorders, deficiency of vitamin K2 results in the deposition of 
calcium in soft tissues such as the heart, and in blood vessel walls, and is 
therefore associated with an increased risk of cardiovascular disorders- this 
results from weakening of heart muscle and/or valves, stiffening of artery 
walls, plaque formation and atherosclerosis.  Vitamin K2 has also been shown 
to have an important role in normal immune function. Vitamin K2 inhibits the 
proliferation of cancer cells, and deficiency has been associated with an 
increased risk of prostate, liver and lung cancers (Kakizaki et al, 2007; Hey & 
Brasen, 2015). 
 
Vitamin K2 deficiency 
A vitamin K deficiency can result from poor diet, alcoholism, smoking, 
malabsorption syndromes and the use of certain types of antibiotic. In 
particular, vitamin K2 levels may be depleted by the use of statins (Okuyama 
et al, 2015).  Nutritional experts consider that a majority of the UK population 
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are vitamin K2 deficient to some degree- levels of vitamin K considered 
sufficient to maintain normal blood clotting may not be sufficient to maintain 
healthy bone structure and cardiovascular function. Vitamin K2 levels are 
essentially nil in processed convenience foods, and low even in a healthy diet. 
As noted above, depletion of vitamin K2 is associated with osteoporosis, 
cardiovascular disease, abnormal blood clotting and increased risk of some 
types of cancer.  
 
A number of clinical studies have reported a link between vitamin K2 
deficiency, arterial calcification and risk of morbidity/mortality. A study of the 
dietary intake of vitamins K1 and K2 in some 5000 subjects over a ten year 
period found that those in the highest third of vitamin K2 intake (the vitamin 
K2 intake ranged from < 21.6 mcg/day in the lowest third to > 32.7 mcg/day 
in the highest third of menaquinone (Vitamin K2) intake) were 52% less likely 
to develop severe calcification of the arteries, 41% less likely to develop 
cardiovascular disease, and 57% less likely to die from cardiovascular disease. 
(Geleijnse et al., 2004). However, intake of vitamin K1 had no effect on these 
cardiovascular disease outcomes. Similarly, a study of vitamin K1/K2 intake in 
16,000 women aged 50-70 years found that participants with the highest 
intake of vitamin K2 had a much lower risk of cardiovascular disease; for every 
10 micrograms of K2/day consumed, the risk of cardiovascular disease was 
reduced by 9% (Gast et al, 2009). 
In haemodialysis patients, vitamin K deficiency may result from poor dietary 
intake, in part due to the dietary limitations imposed by the uremic status 
(Cranenburg et al, 2012; Fusaro et al, 2017), smoking (Fusaro et al, 2017), 
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use of statins (Chen et al, 2017), time on dialysis (Feng et al, 2015), or 
treatment with vitamin K antagonists (Caluwe et al, 2016; Voskamp et al, 
2018). Use of vitamin K antagonists (coumarins; principally warfarin, but also 
phenindione and acenocoumarol) in haemodialysis patients has been linked to 
various adverse outcomes (De Mauri et al, 2017). Vitamin K deficiency has 
been linked to the development of calciphylaxis, an uncommon but frequently 
fatal complication in haemodialysis patients (Nigwekar et al 2017). In this 
small case-control study comprising 40 haemodialysis patients, calciphylaxis 
was associated with a significant reduction in vitamin K mediated carboxylated 
matrix Gla protein, which is required to inhibit vascular calcification. A 
randomised controlled clinical study is currently in progress to determine 
whether supplementation with vitamin K can increase carboxylated Gla protein 
levels in calciphylaxis patients (NCT 02278692). 
 
Unlike the situation with vitamin D3, there is no simple blood test to determine 
whether an individual may be deficient in vitamin K2. A specialised assay is 
available which quantifies the level of uncarboxylated matrix Gla protein, which 
correlates with the level of vitamin K. The European Food Safety Authority 
(EFSA) have not established an NRV (Nutrient Reference Value) for vitamin K2, 
although an adequate intake value has been listed (EFSA Panel on Dietetic 
Products Nutrition and Allergies (NDA), 2017). However, the adequate intake 
value is thought to relate to the liver requirement only (ie for adequate blood 
clotting). Theuwissen et al (2014) provided evidence for a deficiency of vitamin 
K2 in the  general population, on the basis that both children and adults had 
high blood levels of under-carboxylated extra-hepatic proteins MGP and 
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osteocalcin (ie those involved in cardiovascular /bone calcium mobilisation). 
 
Vitamin K2 supplementation in haemodialysis patients 
A number of studies in haemodialysis patients have demonstrated deficiency of 
vitamin K2 and increased levels of uncarboxylated inactive Gla protein and/or 
undercarboxylated osteocalcin (Pilkey et al, 2007; Holden et al, 2011); 
Westenfeld et al, 2012; Bentkowski et al, 2013). The levels of uncarboxylated 
matrix Gla protein correlated with vascular calcification and arterial stiffness in 
end-stage renal disease patients (Thamrattnopkoon et al, 2017).  
 
A clinical study of 200 haemodialysis patients by Caluwe et al (2014)  
demonstrated that supplementation with vitamin K2  for 8 weeks significantly 
(P = 0.023) decreased  the circulatory level of the inactive (uncarboxylated) 
form of vitamin K dependent MGP in a linear and dose dependent fashion, 
thereby helping to prevent vascular calcification.  This study is however limited 
by the absence of a placebo group, although, in nine patients who withdrew 
from the study within the first week, the plasma level of inactive MGP 
remained unchanged. A randomised controlled trial by Caluwe et al 
(NCT02610933) is currently underway to determine whether  the use of the 
anticoagulant rivaroxaban (instead of warfarin) can slow vascular calcification, 
and also whether addition of vitamin K2 to rivaroxaban can further slow or 
prevent vascular calcification. The greatest benefit being obtained at a dose 
equivalent to 360 mcg MK-7/day. Similarly Westenfeld et al (2012) and Aoun 
et al (2017) reported supplementation with 360mcg/day vitamin K2 MK7 for 4-
6 weeks in haemodialysis patients reduced mean uncarboxylated matrix Gla 
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protein by 86% and 93% respectively. In a study of haemodialysis patients in 
which vitamin K was incorporated into the dialysis buffer, over a period of 3 
months arterial calcification was significantly reduced (Li et al, 2017).  
 
Two randomised controlled trials, VitaVasK (Krueger et al, 2014) and iPACK HD 
(Holden et al, 2015), are in progress to determine the effect of vitamin K 
supplementation on the progression of arterial calcification in haemodialysis 
patients; however both trials are using supplemental vitamin K in K1 form, 
rather than K2 form. 
 
It is of note that in patients with chronic kidney disease (stages 2-5) but not 
yet requiring haemodialysis, plasma levels of uncarboxylated Gla (gamma-
carboxyglutamic acid-containing) protein increased progressively with the 
disease stage (Schurgers et al, 2010). 
 
Osteoporosis is another common comorbidity in haemodialysis patients, with a 
four-fold increased risk of hip fracture compared with the general population 
(Iwasaki et al, 2017).  While there is increasing evidence for the benefits of 
vitamin K2 supplementation on bone health in the general population (Huang 
et al, 2015), clinical trials on vitamin K2 for osteoporosis management among 
haemodialysis patients are generally lacking. However, two clinical studies to 
date have shown high dose (45mg/day) vitamin K2 to have a positive impact 
on markers of bone health in CKD patients. In the first study (Yonemura et al, 
2000; Yonemura et al, 2004), oral  supplementation with vitamin K2, alone or 
in combination with vitamin D3, significantly reduced prednisolone induced 
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bone mineral loss in patients with chronic glomerulonephritis. In the second 
study (Sugimoto et al, 2002), oral supplementation with vitamin K2 reduced 
bone mineral loss in ambulatory peritoneal dialysis patients. It should be noted 
that the latter study comprised only 8 patients, and that both the above 
studies used a form of vitamin K2 known as menatetrenone (MK-4), a less 
bioavailable form of vitamin K2 compared to the MK-7 form (Schurgers et al, 
2007). 
 
 
Safety of Vitamin K2 supplementation 
In terms of safety, clinical studies have shown supplementation with vitamin 
K2 to be well tolerated, with incidence of adverse effects similar to placebo. 
With regards to long-term safety, randomised controlled clinical trials typically 
supplement vitamin K2 for 1-5 years (e.g. Vossen et al, 2015), although 
beneficial effects may be seen after 2-3 months (Caluwe et al, 2014). The  
safety of supplemental vitamin K2 for the general population has been 
confirmed in a recent pharmacopeial review (Marles et al, 2017). Vitamin k2 
may interfere with warfarin based anticoagulation therapy, although 
supplementation of some vitamin K at a steady level during anticoagulation 
therapy may result in a more stable INR that requires fewer adjustments (Lurie 
et al., 2010).  
Newer anticoagulation agents such as dabigatran, rivaroxaban, and apixaban 
are not vitamin K-dependent.  
It is important that any oral supplement used is manufactured to 
pharmaceutical standards (for which certificates of analysis should be 
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available).  In the UK food grade supplements are not subject to the same 
regulatory requirements as pharmaceutical medicines, and may contain 
substantially less vitamin K2 than stated on the product labelling. In 2013 
Kappa Bioscience (a manufacturer of supplemental vitamin K2) undertook an 
analytical program by testing 100 vitamin K2 products for label claim. These 
products were purchased from retailers in a variety of product formats and 
formulations. Of these products, 81%  did not meet the stated label claim for 
vitamin K2 MK-7 content, with ten products having no detectable vitamin K2 
content. This is because as a lipid-soluble vitamin, vitamin K2 is susceptible to 
degradation, particularly when in combination with minerals such as calcium or 
magnesium (see www.kappabio.com/k2 stability). In addition to the above, 
supplements should contain 100% vitamin K2 MK-7 in the trans -form, since 
this is the biologically active isomer (the cis- form is biologically inactive). 
 
Summary 
Vitamin K2 supplementation is a safe and cost-effective nutritional strategy 
that may be integrated into the care of haemodialysis patients; vitamin K2 
supplementation has been shown to reduce uncarboxylated matrix Gla protein 
in haemodialysis patients, and may help reduce vascular calcification. There is 
currently no consensus as to the dosage of vitamin K2 to be supplemented in 
haemodialysis patients; however guidance can be obtained from the clinical 
studies described in this review which typically supplemented 360mcg vitamin 
K2/day. On those days on which patients are dialysed, the supplement is 
administered immediately after the dialysis session (Caluwe et al, 2013; Aoun 
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et al, 2017). 
 
Key points 
1. Cardiovascular disease is a major cause of morbidity and mortality in 
patients undergoing haemodialysis. 
2. Cardiovascular disease in haemodialysis patients has been linked with 
severe arterial calcification. 
3. Severe arterial calcification in haemodialysis patients, and in other 
disorders, has been linked with a deficiency of vitamin K2. 
4. Vitamin K2 is a cofactor of the enzyme gamma glutamyl carboxylase, which 
has a key role in activating proteins responsible for transferring calcium from 
arterial linings into bone. 
5. Oral supplementation with vitamin K2 has the potential to reduce arterial 
calcification and hence risk of cardiovascular mortality in haemodialysis 
patients. 
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